OncoMatch/Gastric / Stomach Cancer/MMR / MSI-H
Gastric / Stomach CancerMMR / MSI-H Clinical Trials
Mismatch repair deficiency (dMMR) / microsatellite instability-high (MSI-H) occurs in approximately 4–8% of advanced gastric cancers and defines a highly immunotherapy-sensitive subgroup. Pembrolizumab achieved tumor-agnostic FDA approval for dMMR/MSI-H solid tumors, and nivolumab combinations are approved in the first-line setting. Trials study neoadjuvant immunotherapy for locally advanced MSI-H gastric cancer, checkpoint combinations, and MRD-guided surgery approaches.
Top recruiting MMR / MSI-H Gastric / Stomach Cancer trials
Ranked by phase and US site count. See all 8 trials matched to your profile →
Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
ECOG-ACRIN Cancer Research Group
Tislelizumab Plus FOLFOX Versus POF in the Treatment of Locally Advanced: a Multicenter, Open-label, Randomized Phase III Studyunresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma
Fujian Cancer Hospital
A Clinical Study of Sintilimab Combined With Chemothrapy Versus Chemotherapy as Adjuvant Therapy for Gastric/Gastroesophageal Junction Adenocarcinoma
Fudan University
Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal Tumors
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Synergistic Effects of PD-1 Antibody and Chemotherapy/Targeted Therapy Followed by Surgery-centric Local Treatment in Patients With Limited-metastatic Gastric Cancer
Shanghai Zhongshan Hospital
Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cancer
Fudan University
Browse other molecular targets with active Gastric / Stomach Cancer trials.